Longeveron Inc. (LGVN) Stock Competitors & Peer Comparison
See (LGVN) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LGVN | $0.69 | -1.15% | 14.5M | -0.65 | -$1.13 | N/A |
| VRTX | $524.37 | +5.56% | 126.4B | 26.46 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $645.51 | +3.52% | 64.4B | 13.70 | $45.63 | +0.58% |
| ARGX | $940.44 | +1.37% | 56.3B | 82.08 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.19 | -2.02% | 41.1B | -2.26 | -$4.15 | N/A |
| ALNY | $312.77 | +3.90% | 40.3B | 54.35 | $5.55 | N/A |
| RVMD | $186.17 | -0.60% | 39.9B | -26.52 | -$7.07 | N/A |
| ONC | $293.88 | +3.12% | 31.1B | 65.04 | $4.47 | N/A |
Stock Comparison
LGVN vs VRTX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, VRTX has a market cap of 126.4B. Regarding current trading prices, LGVN is priced at $0.69, while VRTX trades at $524.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas VRTX's P/E ratio is 26.46. In terms of profitability, LGVN's ROE is -2.02%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, LGVN is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check VRTX's competition here
LGVN vs VRNA Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, LGVN is priced at $0.69, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas VRNA's P/E ratio is -102.80. In terms of profitability, LGVN's ROE is -2.02%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, LGVN is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check VRNA's competition here
LGVN vs REGN Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, REGN has a market cap of 64.4B. Regarding current trading prices, LGVN is priced at $0.69, while REGN trades at $645.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas REGN's P/E ratio is 13.70. In terms of profitability, LGVN's ROE is -2.02%, compared to REGN's ROE of +0.14%. Regarding short-term risk, LGVN is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check REGN's competition here
LGVN vs ARGX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ARGX has a market cap of 56.3B. Regarding current trading prices, LGVN is priced at $0.69, while ARGX trades at $940.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ARGX's P/E ratio is 82.08. In terms of profitability, LGVN's ROE is -2.02%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, LGVN is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ARGX's competition here
LGVN vs SGEN Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, LGVN is priced at $0.69, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas SGEN's P/E ratio is -57.19. In terms of profitability, LGVN's ROE is -2.02%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, LGVN is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check SGEN's competition here
LGVN vs RVMDW Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, RVMDW has a market cap of 41.1B. Regarding current trading prices, LGVN is priced at $0.69, while RVMDW trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas RVMDW's P/E ratio is -2.26. In terms of profitability, LGVN's ROE is -2.02%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, LGVN is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for LGVN.Check RVMDW's competition here
LGVN vs ALNY Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ALNY has a market cap of 40.3B. Regarding current trading prices, LGVN is priced at $0.69, while ALNY trades at $312.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ALNY's P/E ratio is 54.35. In terms of profitability, LGVN's ROE is -2.02%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, LGVN is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ALNY's competition here
LGVN vs RVMD Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, LGVN is priced at $0.69, while RVMD trades at $186.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas RVMD's P/E ratio is -26.52. In terms of profitability, LGVN's ROE is -2.02%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, LGVN is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check RVMD's competition here
LGVN vs ONC Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ONC has a market cap of 31.1B. Regarding current trading prices, LGVN is priced at $0.69, while ONC trades at $293.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ONC's P/E ratio is 65.04. In terms of profitability, LGVN's ROE is -2.02%, compared to ONC's ROE of +0.12%. Regarding short-term risk, LGVN is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ONC's competition here
LGVN vs MRNA Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, MRNA has a market cap of 28.8B. Regarding current trading prices, LGVN is priced at $0.69, while MRNA trades at $78.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas MRNA's P/E ratio is -8.90. In terms of profitability, LGVN's ROE is -2.02%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, LGVN is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check MRNA's competition here
LGVN vs ROIV Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ROIV has a market cap of 25.2B. Regarding current trading prices, LGVN is priced at $0.69, while ROIV trades at $34.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ROIV's P/E ratio is -38.89. In terms of profitability, LGVN's ROE is -2.02%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, LGVN is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ROIV's competition here
LGVN vs BNTX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, BNTX has a market cap of 23.8B. Regarding current trading prices, LGVN is priced at $0.69, while BNTX trades at $97.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas BNTX's P/E ratio is -20.33. In terms of profitability, LGVN's ROE is -2.02%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, LGVN is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check BNTX's competition here
LGVN vs UTHR Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, UTHR has a market cap of 23.2B. Regarding current trading prices, LGVN is priced at $0.69, while UTHR trades at $555.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas UTHR's P/E ratio is 20.20. In terms of profitability, LGVN's ROE is -2.02%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, LGVN is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check UTHR's competition here
LGVN vs INSM Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, INSM has a market cap of 23.2B. Regarding current trading prices, LGVN is priced at $0.69, while INSM trades at $109.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas INSM's P/E ratio is -18.61. In terms of profitability, LGVN's ROE is -2.02%, compared to INSM's ROE of -1.30%. Regarding short-term risk, LGVN is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check INSM's competition here
LGVN vs INCY Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, INCY has a market cap of 22.7B. Regarding current trading prices, LGVN is priced at $0.69, while INCY trades at $116.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas INCY's P/E ratio is 15.30. In terms of profitability, LGVN's ROE is -2.02%, compared to INCY's ROE of +0.29%. Regarding short-term risk, LGVN is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check INCY's competition here
LGVN vs BGNE Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, LGVN is priced at $0.69, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas BGNE's P/E ratio is -22.55. In terms of profitability, LGVN's ROE is -2.02%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, LGVN is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check BGNE's competition here
LGVN vs DNA-WT Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, LGVN is priced at $0.69, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, LGVN's ROE is -2.02%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, LGVN is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check DNA-WT's competition here
LGVN vs GMAB Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, GMAB has a market cap of 17B. Regarding current trading prices, LGVN is priced at $0.69, while GMAB trades at $28.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas GMAB's P/E ratio is 19.88. In terms of profitability, LGVN's ROE is -2.02%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, LGVN is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check GMAB's competition here
LGVN vs NBIX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, NBIX has a market cap of 16.9B. Regarding current trading prices, LGVN is priced at $0.69, while NBIX trades at $171.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas NBIX's P/E ratio is 24.24. In terms of profitability, LGVN's ROE is -2.02%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, LGVN is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check NBIX's competition here
LGVN vs ASND Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ASND has a market cap of 16.6B. Regarding current trading prices, LGVN is priced at $0.69, while ASND trades at $272.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ASND's P/E ratio is -110.66. In terms of profitability, LGVN's ROE is -2.02%, compared to ASND's ROE of -56.42%. Regarding short-term risk, LGVN is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ASND's competition here
LGVN vs JAZZ Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, JAZZ has a market cap of 14.9B. Regarding current trading prices, LGVN is priced at $0.69, while JAZZ trades at $240.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas JAZZ's P/E ratio is 18.47. In terms of profitability, LGVN's ROE is -2.02%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, LGVN is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check JAZZ's competition here
LGVN vs BBIO Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, BBIO has a market cap of 14.6B. Regarding current trading prices, LGVN is priced at $0.69, while BBIO trades at $76.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas BBIO's P/E ratio is -19.93. In terms of profitability, LGVN's ROE is -2.02%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, LGVN is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check BBIO's competition here
LGVN vs EXEL Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, EXEL has a market cap of 13.6B. Regarding current trading prices, LGVN is priced at $0.69, while EXEL trades at $55.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas EXEL's P/E ratio is 16.16. In terms of profitability, LGVN's ROE is -2.02%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, LGVN is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check EXEL's competition here
LGVN vs IONS Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, IONS has a market cap of 13.1B. Regarding current trading prices, LGVN is priced at $0.69, while IONS trades at $80.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas IONS's P/E ratio is -46.04. In terms of profitability, LGVN's ROE is -2.02%, compared to IONS's ROE of -0.59%. Regarding short-term risk, LGVN is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check IONS's competition here
LGVN vs KRTX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, LGVN is priced at $0.69, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas KRTX's P/E ratio is -28.09. In terms of profitability, LGVN's ROE is -2.02%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, LGVN is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check KRTX's competition here
LGVN vs AXSM Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, AXSM has a market cap of 12.4B. Regarding current trading prices, LGVN is priced at $0.69, while AXSM trades at $242.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas AXSM's P/E ratio is -62.84. In terms of profitability, LGVN's ROE is -2.02%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, LGVN is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check AXSM's competition here
LGVN vs MDGL Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, LGVN is priced at $0.69, while MDGL trades at $522.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas MDGL's P/E ratio is -40.19. In terms of profitability, LGVN's ROE is -2.02%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, LGVN is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check MDGL's competition here
LGVN vs ARWR Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ARWR has a market cap of 11.3B. Regarding current trading prices, LGVN is priced at $0.69, while ARWR trades at $82.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ARWR's P/E ratio is -37.41. In terms of profitability, LGVN's ROE is -2.02%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, LGVN is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ARWR's competition here
LGVN vs RNAM Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, LGVN is priced at $0.69, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas RNAM's P/E ratio is -17.39. In terms of profitability, LGVN's ROE is -2.02%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, LGVN is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check RNAM's competition here
LGVN vs BMRN Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, BMRN has a market cap of 11.2B. Regarding current trading prices, LGVN is priced at $0.69, while BMRN trades at $58.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas BMRN's P/E ratio is 27.80. In terms of profitability, LGVN's ROE is -2.02%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, LGVN is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check BMRN's competition here
LGVN vs SMMT Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, SMMT has a market cap of 11.2B. Regarding current trading prices, LGVN is priced at $0.69, while SMMT trades at $15.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas SMMT's P/E ratio is -8.99. In terms of profitability, LGVN's ROE is -2.02%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, LGVN is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check SMMT's competition here
LGVN vs TECH Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, TECH has a market cap of 11.1B. Regarding current trading prices, LGVN is priced at $0.69, while TECH trades at $70.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas TECH's P/E ratio is 36.60. In terms of profitability, LGVN's ROE is -2.02%, compared to TECH's ROE of +0.05%. Regarding short-term risk, LGVN is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check TECH's competition here
LGVN vs KRYS Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, KRYS has a market cap of 11B. Regarding current trading prices, LGVN is priced at $0.69, while KRYS trades at $370.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas KRYS's P/E ratio is 49.68. In terms of profitability, LGVN's ROE is -2.02%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, LGVN is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check KRYS's competition here
LGVN vs CYTK Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, CYTK has a market cap of 10.6B. Regarding current trading prices, LGVN is priced at $0.69, while CYTK trades at $86.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas CYTK's P/E ratio is -14.62. In terms of profitability, LGVN's ROE is -2.02%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, LGVN is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check CYTK's competition here
LGVN vs IBRX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, IBRX has a market cap of 9.6B. Regarding current trading prices, LGVN is priced at $0.69, while IBRX trades at $9.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas IBRX's P/E ratio is -28.75. In terms of profitability, LGVN's ROE is -2.02%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, LGVN is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check IBRX's competition here
LGVN vs RXDX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, LGVN is priced at $0.69, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas RXDX's P/E ratio is -56.47. In terms of profitability, LGVN's ROE is -2.02%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, LGVN is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check RXDX's competition here
LGVN vs CORT Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, CORT has a market cap of 9.5B. Regarding current trading prices, LGVN is priced at $0.69, while CORT trades at $89.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas CORT's P/E ratio is 252.80. In terms of profitability, LGVN's ROE is -2.02%, compared to CORT's ROE of +0.08%. Regarding short-term risk, LGVN is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check CORT's competition here
LGVN vs KYMR Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, KYMR has a market cap of 9.4B. Regarding current trading prices, LGVN is priced at $0.69, while KYMR trades at $112.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas KYMR's P/E ratio is -32.35. In terms of profitability, LGVN's ROE is -2.02%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, LGVN is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check KYMR's competition here
LGVN vs HALO Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, HALO has a market cap of 9.1B. Regarding current trading prices, LGVN is priced at $0.69, while HALO trades at $78.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas HALO's P/E ratio is 16.67. In terms of profitability, LGVN's ROE is -2.02%, compared to HALO's ROE of +1.26%. Regarding short-term risk, LGVN is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check HALO's competition here
LGVN vs NUVL Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, LGVN is priced at $0.69, while NUVL trades at $123.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas NUVL's P/E ratio is -21.72. In terms of profitability, LGVN's ROE is -2.02%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, LGVN is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check NUVL's competition here
LGVN vs IMGN Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, LGVN is priced at $0.69, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas IMGN's P/E ratio is -111.55. In terms of profitability, LGVN's ROE is -2.02%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, LGVN is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check IMGN's competition here
LGVN vs ABVX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, LGVN is priced at $0.69, while ABVX trades at $142.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ABVX's P/E ratio is -69.33. In terms of profitability, LGVN's ROE is -2.02%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, LGVN is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ABVX's competition here
LGVN vs ALKS Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ALKS has a market cap of 8.6B. Regarding current trading prices, LGVN is priced at $0.69, while ALKS trades at $53.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ALKS's P/E ratio is 54.44. In terms of profitability, LGVN's ROE is -2.02%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, LGVN is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ALKS's competition here
LGVN vs BPMC Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, LGVN is priced at $0.69, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas BPMC's P/E ratio is -51.58. In terms of profitability, LGVN's ROE is -2.02%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, LGVN is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check BPMC's competition here
LGVN vs TGTX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, TGTX has a market cap of 8.2B. Regarding current trading prices, LGVN is priced at $0.69, while TGTX trades at $51.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas TGTX's P/E ratio is 18.39. In terms of profitability, LGVN's ROE is -2.02%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, LGVN is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check TGTX's competition here
LGVN vs APGE Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, LGVN is priced at $0.69, while APGE trades at $132.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas APGE's P/E ratio is -30.66. In terms of profitability, LGVN's ROE is -2.02%, compared to APGE's ROE of -0.33%. Regarding short-term risk, LGVN is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check APGE's competition here
LGVN vs CERE Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, LGVN is priced at $0.69, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas CERE's P/E ratio is -16.47. In terms of profitability, LGVN's ROE is -2.02%, compared to CERE's ROE of -0.72%. Regarding short-term risk, LGVN is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check CERE's competition here
LGVN vs PCVX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, PCVX has a market cap of 8.1B. Regarding current trading prices, LGVN is priced at $0.69, while PCVX trades at $57.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas PCVX's P/E ratio is -8.15. In terms of profitability, LGVN's ROE is -2.02%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, LGVN is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check PCVX's competition here
LGVN vs PTGX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, PTGX has a market cap of 8B. Regarding current trading prices, LGVN is priced at $0.69, while PTGX trades at $128.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas PTGX's P/E ratio is -69.15. In terms of profitability, LGVN's ROE is -2.02%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, LGVN is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check PTGX's competition here
LGVN vs IMVT Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, IMVT has a market cap of 7.8B. Regarding current trading prices, LGVN is priced at $0.69, while IMVT trades at $38.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas IMVT's P/E ratio is -14.28. In terms of profitability, LGVN's ROE is -2.02%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, LGVN is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check IMVT's competition here
LGVN vs RYTM Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, RYTM has a market cap of 7.6B. Regarding current trading prices, LGVN is priced at $0.69, while RYTM trades at $112.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas RYTM's P/E ratio is -35.27. In terms of profitability, LGVN's ROE is -2.02%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, LGVN is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check RYTM's competition here
LGVN vs MTSR Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, LGVN is priced at $0.69, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas MTSR's P/E ratio is -23.58. In terms of profitability, LGVN's ROE is -2.02%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, LGVN is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check MTSR's competition here
LGVN vs LQDA Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, LQDA has a market cap of 7.1B. Regarding current trading prices, LGVN is priced at $0.69, while LQDA trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas LQDA's P/E ratio is 566.57. In terms of profitability, LGVN's ROE is -2.02%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, LGVN is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check LQDA's competition here
LGVN vs MRUS Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, LGVN is priced at $0.69, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas MRUS's P/E ratio is -17.05. In terms of profitability, LGVN's ROE is -2.02%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, LGVN is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check MRUS's competition here
LGVN vs PRAX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, PRAX has a market cap of 6.8B. Regarding current trading prices, LGVN is priced at $0.69, while PRAX trades at $315.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas PRAX's P/E ratio is -23.90. In terms of profitability, LGVN's ROE is -2.02%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, LGVN is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check PRAX's competition here
LGVN vs PTCT Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, PTCT has a market cap of 6.7B. Regarding current trading prices, LGVN is priced at $0.69, while PTCT trades at $81.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas PTCT's P/E ratio is -34.91. In terms of profitability, LGVN's ROE is -2.02%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, LGVN is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check PTCT's competition here
LGVN vs ACLX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, LGVN is priced at $0.69, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ACLX's P/E ratio is -28.27. In terms of profitability, LGVN's ROE is -2.02%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, LGVN is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ACLX's competition here
LGVN vs COGT Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, COGT has a market cap of 6.6B. Regarding current trading prices, LGVN is priced at $0.69, while COGT trades at $38.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas COGT's P/E ratio is -18.24. In terms of profitability, LGVN's ROE is -2.02%, compared to COGT's ROE of -0.83%. Regarding short-term risk, LGVN is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check COGT's competition here
LGVN vs RETA Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, LGVN is priced at $0.69, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas RETA's P/E ratio is -66.29. In terms of profitability, LGVN's ROE is -2.02%, compared to RETA's ROE of +0.47%. Regarding short-term risk, LGVN is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check RETA's competition here
LGVN vs SRRK Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, SRRK has a market cap of 6.3B. Regarding current trading prices, LGVN is priced at $0.69, while SRRK trades at $53.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas SRRK's P/E ratio is -14.72. In terms of profitability, LGVN's ROE is -2.02%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, LGVN is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check SRRK's competition here
LGVN vs CNTA Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, LGVN is priced at $0.69, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas CNTA's P/E ratio is -22.63. In terms of profitability, LGVN's ROE is -2.02%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, LGVN is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check CNTA's competition here
LGVN vs LGND Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, LGND has a market cap of 6.3B. Regarding current trading prices, LGVN is priced at $0.69, while LGND trades at $315.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas LGND's P/E ratio is 37.41. In terms of profitability, LGVN's ROE is -2.02%, compared to LGND's ROE of +0.16%. Regarding short-term risk, LGVN is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check LGND's competition here
LGVN vs CGON Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, LGVN is priced at $0.69, while CGON trades at $69.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas CGON's P/E ratio is -30.42. In terms of profitability, LGVN's ROE is -2.02%, compared to CGON's ROE of -0.23%. Regarding short-term risk, LGVN is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check CGON's competition here
LGVN vs MIRM Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, LGVN is priced at $0.69, while MIRM trades at $123.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas MIRM's P/E ratio is -8.85. In terms of profitability, LGVN's ROE is -2.02%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, LGVN is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check MIRM's competition here
LGVN vs BLTE Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, BLTE has a market cap of 5.7B. Regarding current trading prices, LGVN is priced at $0.69, while BLTE trades at $145.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas BLTE's P/E ratio is -76.10. In terms of profitability, LGVN's ROE is -2.02%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, LGVN is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check BLTE's competition here
LGVN vs CDTX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, LGVN is priced at $0.69, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas CDTX's P/E ratio is -19.77. In terms of profitability, LGVN's ROE is -2.02%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, LGVN is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check CDTX's competition here
LGVN vs ERAS Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ERAS has a market cap of 5.6B. Regarding current trading prices, LGVN is priced at $0.69, while ERAS trades at $18.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ERAS's P/E ratio is -40.73. In terms of profitability, LGVN's ROE is -2.02%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, LGVN is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ERAS's competition here
LGVN vs LEGN Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, LEGN has a market cap of 5.5B. Regarding current trading prices, LGVN is priced at $0.69, while LEGN trades at $29.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas LEGN's P/E ratio is -43.96. In terms of profitability, LGVN's ROE is -2.02%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, LGVN is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check LEGN's competition here
LGVN vs ABCM Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, LGVN is priced at $0.69, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, LGVN's ROE is -2.02%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, LGVN is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ABCM's competition here
LGVN vs ISEE Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, LGVN is priced at $0.69, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ISEE's P/E ratio is -22.44. In terms of profitability, LGVN's ROE is -2.02%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, LGVN is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ISEE's competition here
LGVN vs SYRE Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, SYRE has a market cap of 5.4B. Regarding current trading prices, LGVN is priced at $0.69, while SYRE trades at $86.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas SYRE's P/E ratio is -42.74. In terms of profitability, LGVN's ROE is -2.02%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, LGVN is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check SYRE's competition here
LGVN vs CRSP Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, LGVN is priced at $0.69, while CRSP trades at $59.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas CRSP's P/E ratio is -10.88. In terms of profitability, LGVN's ROE is -2.02%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, LGVN is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check CRSP's competition here
LGVN vs MANE Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, MANE has a market cap of 5.3B. Regarding current trading prices, LGVN is priced at $0.69, while MANE trades at $128.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas MANE's P/E ratio is -40.70. In terms of profitability, LGVN's ROE is -2.02%, compared to MANE's ROE of -0.95%. Regarding short-term risk, LGVN is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check MANE's competition here
LGVN vs CAI Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, CAI has a market cap of 5.3B. Regarding current trading prices, LGVN is priced at $0.69, while CAI trades at $18.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas CAI's P/E ratio is -103.14. In terms of profitability, LGVN's ROE is -2.02%, compared to CAI's ROE of +0.06%. Regarding short-term risk, LGVN is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check CAI's competition here
LGVN vs APLS Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, LGVN is priced at $0.69, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas APLS's P/E ratio is 38.35. In terms of profitability, LGVN's ROE is -2.02%, compared to APLS's ROE of +0.40%. Regarding short-term risk, LGVN is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check APLS's competition here
LGVN vs TVTX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, LGVN is priced at $0.69, while TVTX trades at $55.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas TVTX's P/E ratio is -256.09. In terms of profitability, LGVN's ROE is -2.02%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, LGVN is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check TVTX's competition here
LGVN vs CELC Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, CELC has a market cap of 5.1B. Regarding current trading prices, LGVN is priced at $0.69, while CELC trades at $106.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas CELC's P/E ratio is -26.79. In terms of profitability, LGVN's ROE is -2.02%, compared to CELC's ROE of -2.45%. Regarding short-term risk, LGVN is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check CELC's competition here
LGVN vs TERN Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, LGVN is priced at $0.69, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas TERN's P/E ratio is -51.41. In terms of profitability, LGVN's ROE is -2.02%, compared to TERN's ROE of -0.20%. Regarding short-term risk, LGVN is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check TERN's competition here
LGVN vs XENE Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, XENE has a market cap of 4.8B. Regarding current trading prices, LGVN is priced at $0.69, while XENE trades at $60.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas XENE's P/E ratio is -12.83. In terms of profitability, LGVN's ROE is -2.02%, compared to XENE's ROE of -0.49%. Regarding short-term risk, LGVN is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check XENE's competition here
LGVN vs DFTX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, LGVN is priced at $0.69, while DFTX trades at $43.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas DFTX's P/E ratio is N/A. In terms of profitability, LGVN's ROE is -2.02%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, LGVN is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check DFTX's competition here
LGVN vs FOLD Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, LGVN is priced at $0.69, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas FOLD's P/E ratio is -161.00. In terms of profitability, LGVN's ROE is -2.02%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, LGVN is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check FOLD's competition here
LGVN vs AKRO Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, LGVN is priced at $0.69, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas AKRO's P/E ratio is -14.57. In terms of profitability, LGVN's ROE is -2.02%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, LGVN is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check AKRO's competition here
LGVN vs ALPN Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, LGVN is priced at $0.69, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ALPN's P/E ratio is -101.52. In terms of profitability, LGVN's ROE is -2.02%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, LGVN is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ALPN's competition here
LGVN vs VKTX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, VKTX has a market cap of 4.4B. Regarding current trading prices, LGVN is priced at $0.69, while VKTX trades at $36.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas VKTX's P/E ratio is -9.05. In terms of profitability, LGVN's ROE is -2.02%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, LGVN is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check VKTX's competition here
LGVN vs ACAD Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, LGVN is priced at $0.69, while ACAD trades at $25.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ACAD's P/E ratio is 12.35. In terms of profitability, LGVN's ROE is -2.02%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, LGVN is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ACAD's competition here
LGVN vs NAMSW Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, NAMSW has a market cap of 4.3B. Regarding current trading prices, LGVN is priced at $0.69, while NAMSW trades at $23.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas NAMSW's P/E ratio is -12.96. In terms of profitability, LGVN's ROE is -2.02%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, LGVN is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check NAMSW's competition here
LGVN vs OPT Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, LGVN is priced at $0.69, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas OPT's P/E ratio is -1.52. In terms of profitability, LGVN's ROE is -2.02%, compared to OPT's ROE of +1.18%. Regarding short-term risk, LGVN is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check OPT's competition here
LGVN vs EWTX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, EWTX has a market cap of 4.2B. Regarding current trading prices, LGVN is priced at $0.69, while EWTX trades at $39.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas EWTX's P/E ratio is -23.58. In terms of profitability, LGVN's ROE is -2.02%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, LGVN is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check EWTX's competition here
LGVN vs DNLI Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, DNLI has a market cap of 4.1B. Regarding current trading prices, LGVN is priced at $0.69, while DNLI trades at $25.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas DNLI's P/E ratio is -9.02. In terms of profitability, LGVN's ROE is -2.02%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, LGVN is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check DNLI's competition here
LGVN vs MRTX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, LGVN is priced at $0.69, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas MRTX's P/E ratio is -4.82. In terms of profitability, LGVN's ROE is -2.02%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, LGVN is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check MRTX's competition here
LGVN vs NAMS Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, NAMS has a market cap of 4.1B. Regarding current trading prices, LGVN is priced at $0.69, while NAMS trades at $34.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas NAMS's P/E ratio is -22.12. In terms of profitability, LGVN's ROE is -2.02%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, LGVN is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check NAMS's competition here
LGVN vs CRNX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, CRNX has a market cap of 4.1B. Regarding current trading prices, LGVN is priced at $0.69, while CRNX trades at $42.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas CRNX's P/E ratio is -7.54. In terms of profitability, LGVN's ROE is -2.02%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, LGVN is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check CRNX's competition here
LGVN vs TLX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, TLX has a market cap of 4B. Regarding current trading prices, LGVN is priced at $0.69, while TLX trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas TLX's P/E ratio is -644.53. In terms of profitability, LGVN's ROE is -2.02%, compared to TLX's ROE of -0.02%. Regarding short-term risk, LGVN is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check TLX's competition here
LGVN vs CPRX Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, LGVN is priced at $0.69, while CPRX trades at $31.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas CPRX's P/E ratio is 11.31. In terms of profitability, LGVN's ROE is -2.02%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, LGVN is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check CPRX's competition here
LGVN vs DNTH Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, DNTH has a market cap of 3.8B. Regarding current trading prices, LGVN is priced at $0.69, while DNTH trades at $92.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas DNTH's P/E ratio is -21.84. In terms of profitability, LGVN's ROE is -2.02%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, LGVN is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check DNTH's competition here
LGVN vs RYZB Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, LGVN is priced at $0.69, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas RYZB's P/E ratio is -57.86. In terms of profitability, LGVN's ROE is -2.02%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, LGVN is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check RYZB's competition here
LGVN vs CBAY Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, LGVN is priced at $0.69, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas CBAY's P/E ratio is -32.81. In terms of profitability, LGVN's ROE is -2.02%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, LGVN is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check CBAY's competition here
LGVN vs DYN Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, DYN has a market cap of 3.6B. Regarding current trading prices, LGVN is priced at $0.69, while DYN trades at $22.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas DYN's P/E ratio is -6.77. In terms of profitability, LGVN's ROE is -2.02%, compared to DYN's ROE of -0.58%. Regarding short-term risk, LGVN is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check DYN's competition here
LGVN vs ADPT Comparison July 2026
LGVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGVN stands at 14.5M. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, LGVN is priced at $0.69, while ADPT trades at $21.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGVN currently has a P/E ratio of -0.65, whereas ADPT's P/E ratio is -41.43. In terms of profitability, LGVN's ROE is -2.02%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, LGVN is more volatile compared to ADPT. This indicates potentially higher risk in terms of short-term price fluctuations for LGVN.Check ADPT's competition here